Rich Woessner

607 total citations
17 papers, 326 citations indexed

About

Rich Woessner is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rich Woessner has authored 17 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rich Woessner's work include Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Mechanisms and Therapy (3 papers). Rich Woessner is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Mechanisms and Therapy (3 papers). Rich Woessner collaborates with scholars based in United States, South Korea and Japan. Rich Woessner's co-authors include Joseph P. Lyssikatos, Joshua D. Hansen, M. Bruce Welch, Guy Vigers, Tony Morales, Matthew Martinson, Ellen R. Laird, Barbara J. Brandhuber, Jonas Grina and Alan G. Olivero and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Rich Woessner

15 papers receiving 318 citations

Peers

Countries citing papers authored by Rich Woessner

Since Specialization

Citations

This map shows the geographic impact of Rich Woessner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rich Woessner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rich Woessner more than expected).

Fields of papers citing papers by Rich Woessner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rich Woessner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rich Woessner. The network helps show where Rich Woessner may publish in the future.

Co-authorship network of co-authors of Rich Woessner

This figure shows the co-authorship network connecting the top 25 collaborators of Rich Woessner. A scholar is included among the top collaborators of Rich Woessner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rich Woessner. Rich Woessner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer 2024 ·Therapeutic Advances in Medical Oncology ·Sun Min Lim, Stefanie S. Schalm, (unknown), Sewon Park, Chiara Conti, Yves Millet, Rich Woessner, Zhuo Zhang, Luz E. Tavera-Mendoza, Faith Stevison, Faris Albayya, Thomas A. Dineen, (unknown), (unknown), Alena Zalutskaya, Julia Rotow, Kōichi Goto, Dae-Ho Lee, Mi Ran Yun, Byoung Chul Cho	7
2	Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC) 2021 ·Cancer Research ·Sun Min Lim, Chae Won Park, Zhuo Zhang, Rich Woessner, (unknown), Faith Stevison, (unknown), (unknown), (unknown), John Campbell, (unknown), Faris Albayya, (unknown), Marion Dorsch, Klaus P. Hoeflich, Byoung Chul Cho, Stefanie S. Schalm	17
3	1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC 2020 ·Annals of Oncology ·Stefanie S. Schalm, (unknown), Sangbin Lim, (unknown), (unknown), Rich Woessner, (unknown), Kevin Wilson, (unknown), Douglas Wilson, Brett Williams, John Campbell, Chris De Savi, Faith Stevison, (unknown), (unknown), Marion Dorsch, Klaus P. Hoeflich, (unknown)	43
4	384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC 2020 ·Annals of Oncology ·Stefanie S. Schalm, (unknown), Sangbin Lim, (unknown), (unknown), Rich Woessner, (unknown), Kevin Wilson, (unknown), Douglas Wilson, Brett Williams, John Campbell, Chris De Savi, Faith Stevison, (unknown), (unknown), Marion Dorsch, Klaus P. Hoeflich, Byoung Chul Cho	12
5	Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response 2020 ·Clinical Cancer Research ·(unknown), Pei Zhang, Kelly Goodwin, Greg O’Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda S. Merchant, Gayle P. Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris F. Sachsenmeier	68
6	Abstract 3684: Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models 2017 ·Cancer Research ·Rich Woessner, Vasu R. Sah, Patricia McCoon, Shaun Grosskurth, Nanhua Deng, Rachel DuPont, Deborah Lawson, Lourdes Pablo, Corinne Reimer, Marco A. De Velasco, Hirotsugu Uemura, Juliana Candido, Paul D. Lyne	1
7	Abstract A93: STAT3 inhibition enhances the activity of immune checkpoint inhibitors in murine syngeneic tumor models by creating a more immunogenic tumor microenvironment 2015 ·Cancer Immunology Research ·Rich Woessner, Patricia McCoon, Kirsten Bell, Rachel DuPont, Michael P. Collins, (unknown), (unknown), Lourdes Pablo, Corinne Reimer, Vasu R. Sah, Paul D. Lyne	2
8	Abstract CT239: Clinical and preclinical evidence of an immune modulating role for the STAT3-targeting ASO AZD9150 and potential to enhance clinical responses to anti-PDL1 therapy 2015 ·Cancer Research ·Patricia McCoon, Rich Woessner, Shaun Grosskurth, Chris Womack, Mason Yamashita, (unknown), Robert A. MacLeod, Kirsten Bell, Michael P. Collins, Rachel DuPont, (unknown), Michele Johnstone, Margaret H. Veldman-Jones, Paul D. Lyne	1
9	Non-oxime pyrazole based inhibitors of B-Raf kinase 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Joshua D. Hansen, Jonas Grina, M. Bruce Welch, (unknown), (unknown), (unknown), Matthew Martinson, Sarah Galbraith, Ellen R. Laird, Barbara J. Brandhuber, Guy Vigers, Tony Morales, Rich Woessner, (unknown), Joseph P. Lyssikatos, Alan G. Olivero	38
10	Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2. 2009 ·Cancer Research ·(unknown), Karyn Bouhana, Deborah Anderson, Jennifer Garrus, Kateri A. Ahrendt, Shelley Allen, Ira von Carlowitz, (unknown), Stefan Groß, Keith L. Hoffman, Christine Lemieux, Joe Lyssikatos, (unknown), (unknown), Eli Wallace, Shannon L. Winski, Rich Woessner, Qian Zhao, (unknown), Patrice Lee	20
11	Differential activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 compared to lapatanib in in vivo xenograft models 2008 ·Cancer Research ·Karyn Bouhana, (unknown), Rich Woessner, (unknown), Ira von Carlowitz, Keith L. Hoffman, Eli Wallace, Kevin M. Koch, (unknown), Shannon L. Winski, Patrice Lee	0
12	Potent and selective pyrazole-based inhibitors of B-Raf kinase 2008 ·Bioorganic & Medicinal Chemistry Letters ·Joshua D. Hansen, Jonas Grina, Brad Newhouse, M. Bruce Welch, (unknown), (unknown), (unknown), Susan L. Gloor, Matthew Martinson, Ellen R. Laird, Barbara J. Brandhuber, Guy Vigers, Tony Morales, Rich Woessner, (unknown), Joseph P. Lyssikatos, Alan G. Olivero	57
13	Characterization of the Effects of Pim Kinase Inhibition on Multiple Oncogene-Driven Cell Lines 2008 ·Blood ·Stefan Groß, John Robinson, Shelley Allen, April Cox, (unknown), Sarah Galbraith, Patrice Lee, Christine Lemieux, Joseph P. Lyssikatos, (unknown), Matthew Martinson, Mark Munson, Ross Wallace, Rich Woessner, John S. Zuzack, James D. Winkler, Kevin M. Koch	1
14	ARRY-649, a member of a novel class of Eg5 kinesin inhibitors 2006 ·Journal of Clinical Oncology ·Mark Miglarese, (unknown), Rich Woessner, Shelley Allen, (unknown), Christine Lemieux, (unknown), Joe Lyssikatos, (unknown), Kevin M. Koch	3
15	ARRY-429520, a Novel KSP Inhibitor with Potent Anti-Proliferative Activity in Leukemic Cell Lines. 2006 ·Blood ·Christine Lemieux, (unknown), (unknown), Eli Wallace, Rich Woessner, (unknown), Shelley Allen, (unknown), Qian Zhao, (unknown), Joe Lyssikatos, John Robinson, Kevin M. Koch, James D. Winkler, Stefan Groß	1
16	Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones 2005 ·Journal of Medicinal Chemistry ·Eli M. Wallace, Joseph P. Lyssikatos, James F. Blake, Jeongbeob Seo, Hong Woon Yang, Tammie C. Yeh, (unknown), (unknown), Vivienne Marsh, G Pöch, (unknown), Jennifer Otten, Gary P. Hingorani, Rich Woessner, Patrice Lee, James D. Winkler, Kevin M. Koch	34
17	The effect of lithium on the membrane molecular dynamics of normal human erythrocytes 1987 ·Biological Psychiatry ·Jay W. Pettegrew, (unknown), Rich Woessner, Sandra Strychor, (unknown), (unknown), Nancy J. Minshew, A. John Rush	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact